Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: Evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia

Circulation Research

Volumn 93, Issue 3, 2003, Pages 254-261

  Tanno, Masaya ^a   Bassi, Rekha ^a   Gorog, Diana A ^a   Saurin, Adrian T ^a   Jiang, Jie ^e   Heads, Richard J ^a   Martin, Jody L ^a   Davis, Roger J ^b   Flavell, Richard A ^c   Marber, Michael S ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e NONE

Author keywords

Ischemic preconditioning; Mitogen activated protein kinase kinase 3; Myocardial infarction; p38 mitogen activated protein kinase; TAB1

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; PROTEIN TAB1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BINDING; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VOLUME; MALE; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; DISEASE PROGRESSION; ENZYME ACTIVATION; ENZYME INHIBITORS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE KINASE 3; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MYOBLASTS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIDINES; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042525992     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000083490.43943.85     Document Type: Article

References (33)

1. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS. Antiischemic effects of SB203580 are mediated through the inhibition of p38α mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circ Res. 2001;89:750-752.
2. Ping P, Murphy E. Role of p38 mitogen-activated protein kinase in preconditioning: a detrimental factor or a protective kinase? Circ Res. 2000;86:921-922.
3. Saurin AT, Martin JL, Heads RJ, Foley C, Mockridge JW, Wright MJ, Wang Y, Marber MS. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J. 2000;14:2237-2246.
4. Nagarkatti DS, Ramadan IS. Role of p38 MAP kinase in myocardial stress. J Mol Cell Cardiol. 1998;30:1651-1664.
5. Barancik M, Htun P, Strohm C, Kilian K, Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol. 2000;35:474-483.
6. Ma X, Kumar S, Gao F, Louden C, Lopez B, Christopher T, Wang C, Lee J, Feuerstein G, Yue T. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99:1685-1691.
7. Yue T-L, Wang C, Gu J-L, Ma X-L, Kumar S, Lee JC, Feuersten GZ, Thaoms H, Maleeff B, Ohlstein EH. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000;86:692-699.
8. Gysembergh A, Simkhovich BZ, Kloner RA, Przyklenk K. p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart. J Mol Cell Cardiol. 2001;33:681-690.
9. Schneider S, Chen WN, Hou J, Steenbergen C, Murphy E. Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol. 2001;280:H499-H508.
10. Wang Y, Huang S, Sah VP, Ross J, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen activated protein kinase family. J Biol Chem. 1998;273:4:2161-2168.
11. Wysk M, Yang DD, Lu H-T, Flavell RA, Davis RJ. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumour necrosis factor induced cytokine expression. Proc Natl Acad Sci U S A. 1999;96:3763-3768.
12. Chang CI, Xu B, Akella R, Cobb MH, Goldsmith EJ. Crystal structures of MAP Kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell. 2002;9:1241-1249.
13. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, Wang Y. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA. 2001;98:12283-12288.
14. Lu H-T, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, Flavell RA. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (mkk3)-deficient mice. EMBO J. 1999;18:1845-1857.
15. Saurin AT, Pennington DJ, Raat H, Owen MJ, Marber MS. Targetted disruption of the protein kinase C-ε gene abolishes the infarct size reduction that follows ischemic preconditioning of isolated buffer-perfused mouse hearts. Cardiovasc Res. 2002;55:672-680.
16. Xing H, Zhang S, Weinheimer C, Kovacs A. Muslin A. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J. 2000;19:349-358.
17. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79:143-180.
18. Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. MAPKK-independent activation of p386α mediated by TAB1-dependent autophosphorylation of p38α. Science. 2002;295:1291-1294.
19. Wysk M, Yang DD, Lu H-T, Flavell RA, Davis RJ. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumour necrosis factor induced cytokine expression. Proc Natl Acad Sci USA. 1999;96:3763-3768.
20. Mann DL, Deswal A, Bozkurt B, Torre-Amione G. New therapeutics for chronic heart failure. Annu Rev Med. 2002;53:59-74.
21. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059-SB 203580 also inhibits thromboxane synthase. J Biol Chem. 1998;273:28766-28772.
22. Lali FV, Hunat AE, Turner SJ, Foxwell BMJ. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 2000;275:7395-7402.
23. Clerk A, Sugden P. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinase/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 1998;426:93-96.
24. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999;6:559-568.
25. Eyers PA, van den Ijssel P, Quinlan RA, Goedert M, Cohen P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB203580. FEBS Lett. 1999;451:191-196.
26. Gum RJ, McLaughlin MM, Kumar S, Wang ZL, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem. 1998;273:15605-15610.
27. Rakhit RD, Kabir AN, Mockridge JW, Saurin A, Marber MS. Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury. Biochem Biophys Res Commun. 2001;286:995-1002.
28. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, Vlahos CJ. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK α is the predominant isoform expressed in human heart. J Mol Cell Cardiol. 2001;33:1527-1540.
29. Maulik N, Yoshida T, Zu Y-L, Sat M, Banerjee A, Das DK. Ischemic preconditioning triggers tyrosine kinase signalling: a potential role for MAPKAP kinase 2. Am J Physiol. 1998;275:H1857-H1864.
30. Weston CR, Lambright DG, Davis RJ. Signal transduction: MAP kinase signaling specificity. Science. 2002;296:2345-2347.
31. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
32. Nakano M, Knowlton A, Dibbs Z, Mann D. Tumor necrosis factor-α confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 1998;97:1392-1400.
33. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF α and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509-518.